MSc / MPharm in Chemistry, Analytical Chemistry. Pharmaceutical Analysis or related field. 1 - 4 years of relevant experience in Analytical Development
In a landmark step for diabetes management, the U.S. Food and Drug Administration (FDA) has cleared the first over-the-counter (OTC) continuous glucose monitor (CGM) for use in children. The decision expands the indication of Dexcom’s Stelo Glucose Biosensor System, making it the first prescription-free CGM available for pediatric patients.
Government of Punjab, Health and Family Welfare Department (Health-5 Branch) vide letter memo Taighan 01/09/2020-2 Mi5 (Th.D.)/597-598 dated 30.06.2023 to: 1105650: HFW-HLH5021/55/2026-3H5/1/1375227/2026 dated 22.04.2026 has approved the filling of 350+104 (total 454) vacant posts of Pharmacist (Pharmacy Officer) under Mid Day Family Welfare Department Punjab through direct recruitment.
D.Pharma / B.Pharma or Intermediate Vocational Course in Pharmacy recognized by Govt. Must have registered in A.P Pharmacy Council with upto date Renewal.
M.E / M.Tech./ M.Pharm / M.Sc.Tech or an equivalent degree(a minimum of 60%aggregate) in Biotechnology, Pharmacy, Microbiology, Life Sciences or related discipline
Masters Degree in Pharmacology, Life Sciences from a recognized university. Experience in the Research field and scientific writing. Candidates with proficiency in computer application will be preferred.
B-Pharm / Diploma in Pharmacy. District Health Association Vellore District Medical - Public Health Department Vellore, District Health Association invites applications for the following posts on a fully temporary basis on a contractual basis.
First class Masters Degree in Bioinformatics / Biotechnology / Computational Biology / or related areas or Bachelors Degree in Engineering or Technology or Medicine with specialization in Bioinformatics / Biotechnology
M.Sc. / M.Tech. in Life Sciences / Biotechnology / Agricultural Biotechnology, Any national level examination or eligibility test such as CSIR-UGC, NET, GATE, DBT.
Johnson & Johnson has announced encouraging results from its pivotal Phase 2/3 ENERGY study evaluating IMAAVY (nipocalimab-aahu) in patients with warm autoimmune hemolytic anemia (wAIHA), a rare autoimmune blood disorder that currently has no FDA-approved therapies. The findings suggest that the investigational treatment could offer a much-needed targeted option for patients struggling with chronic anemia and severe fatigue.
Danish pharmaceutical giant Novo Nordisk has disclosed an IT security incident that resulted in unauthorized access to a limited number of its internal systems, including data related to some clinical trial participants. The company stated that certain non-public information was copied externally without authorization and that an investigation is currently underway.